Enveric Biosciences (NASDAQ:ENVB) Posts Earnings Results

Enveric Biosciences (NASDAQ:ENVB) announced its quarterly earnings data on Friday. The company reported ($0.76) earnings per share (EPS) for the quarter, FiscalAI reports.

Enveric Biosciences Stock Up 1.7%

Shares of ENVB traded up $0.03 during mid-day trading on Friday, hitting $1.53. The stock had a trading volume of 55,644 shares, compared to its average volume of 1,734,308. The company has a market cap of $5.65 million, a PE ratio of -0.07 and a beta of 1.13. The company’s fifty day simple moving average is $1.44 and its two-hundred day simple moving average is $2.12. Enveric Biosciences has a fifty-two week low of $1.25 and a fifty-two week high of $17.64.

Wall Street Analyst Weigh In

Several brokerages recently commented on ENVB. Wall Street Zen upgraded Enveric Biosciences from a “sell” rating to a “hold” rating in a report on Sunday, July 12th. Weiss Ratings restated a “sell (e+)” rating on shares of Enveric Biosciences in a report on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company has a consensus rating of “Sell”.

Enveric Biosciences Company Profile

Enveric Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of novel psychedelic-based therapeutics for the treatment of psychiatric and neurological disorders. The company’s research platform leverages proprietary medicinal chemistry to design, synthesize and optimize molecules derived from established psychoactive compounds, with a goal of improving safety, efficacy and tolerability compared with traditional formulations.

Enveric’s preclinical pipeline features synthetic analogs of ibogaine, psilocybin and MDMA, each engineered to enhance therapeutic outcomes in conditions such as post-traumatic stress disorder, major depressive disorder and anxiety.